Antigipertenziv preparatlarning kognitiv funksiyalarga ta’siri
Annotatsiya
Jahon Sog’liqni Saqlash Tashkiloti ma’lumotlariga ko’ra, dunyoda 1,13 milliard kishi arterial gipertenziyadan aziyat chekadi, bularning atigi 21% i to’g’ri nazorat ostida. Demensiya hozirda dunyoda 55 million kishining hayot sifatiga salbiy ta’sir qiladi va har 3,2 sekundda bitta yangi holat qayd etiladi. Antigipertenziv preparatlarning kognitiv funksiyaga ta’sirini tahlil qilish va demensiya rivojlanishiga qarshi himoya mexanizmlarini baholashhozirda dolzarb masalardan biri hisoblanadi.Antigipertenziv preparatlarning kognitiv funksiyaga ta’siri faqat qon bosimining pasayishi hisobiga emas , balki mustaqil neyroprotektiv mexanizmlar bilan bog’liqligi haqida ishonchli manbalar mavjud. Angiotenzin retseptor blokatorlari boshqa antigipertenziv preparatlarga nisbatan demensiya riskini 12-26% ga kamaytiradi. Kalsiy kanal blokatorlari beta-blokatorlarga nisbatan 17% ko’proq neyroprotektiv ta’sir ko’rsatadi. Beta-blokatorlar boshqa sinf preparatlarga nisbatan demensiya xavfi bo’yicha kamroq samaradorlik ko’rsatadi.Angiotenzin retseptor blokatorlari va kalsiy kanal blokatorlari eng yaxshi neyroprotektiv xususiyatlarga ega bo’lib, kognitiv funksiyani himoya qilishda afzalroq hisoblanadi. Ushbu ta’sirlar qon bosimini pasaytirish mexanizmlaridan mustaqil ravishda amalga oshadi.
Mualliflar haqida
Adabiyotlar ro'yxati
Mehanna M, McDonough CW, Smith SM, Gong Y, Gums JG, Chapman AB, Johnson JA, Cooper- DeHoff RM. Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers. Clin Transl Sci. 2024;17:e13816. https://doi.org/10.1111/cts.13816.
Carnovale C, Perrotta C, Baldelli S, Cattaneo D, Montrasio C, Barbieri SS, Pompilio G, Vantaggiato C, Clementi E, Pozzi M. Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects. Cardiovascular Research. 2023;119(3):647-667. https://doi.org/10.1093/cvr/cvac110.
Rahnemayan S, Mehdizadehfar E, Fathalizadeh A. Modulating Cognitive Function with Antihypertensive Medications: a Comprehensive Systematic Review On FMRI Studies. Clin Neuroradiol. 2025;35:231-237. https://doi.org/10.1007/s00062-024-01494-0.
den Brok MG, van Dalen JW, Abdulrahman H, et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. JAMDA. 2021;22(7):1386-1395. https://doi.org/10.1016/j.jamda.2020.12.019.
Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD004034. https://doi.org/10.1002/14651858.CD004034.pub4.
Henley B, Okafor M, Kulshreshtha A, et al. Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials. International Journal of Stroke. 2023;18(6):736- 744. https://doi.org/10.1177/17474930231153313.
D’Silva E, Meor Azlan NF, Zhang J. Angiotensin II Receptor Blockers in the Management of Hypertension in Preventing Cognitive Impairment and Dementia—A Systematic Review. Pharmaceutics. 2022;14(10):2123. https://doi.org/10.3390/pharmaceutics14102123.
Zhao X, Lin X, Yu J. Effects of Renin-Angiotensin-Aldosterone System Blockade Medications on Cognition Function in Hypertension: Head-to-Head Comparisons of Various Classes of Antihypertensive Drugs – Overview and Meta-Analyses. Journal of Hypertension. 2016;34:e487
Prasad D, Shkreli L, De Giorgi R, Costi S, Reinecke A. Acute angiotensin receptor blockade and mnemonic discrimination in healthy participants. Journal of Affective Disorders. 2025;375:293-296. https://doi.org/ 10.1016/j.jad.2025.01.119.
Peto OR 0.80, 95% CI 0.68-0.94) (Lam A, Ip R, Chan A, Yiu K, Tsoi K. Renin-angiotensin system inhibitor is better in slowing progression of mild cognitive impairment (MCI): A meta-analysis on antihypertensive drug and risk of dementia in MCI patient. Journal of Hypertension. 2023;41(e-Supplement 3):e162. https://doi.org/10.1097/01.hjh.0000940295.26285.e3.
Nagy A, Májer R, Csikai E, et al. The Correlation between Two Angiotensin-Converting Enzyme Inhibitor’s Concentrations and Cognition. International Journal of Environmental Research and Public Health. 2022;19(21):14375. https://doi.org/10.3390/ijerph192114375.
Rogers SC, Ko YA, Quyyumi AA, Hajjar I. Differential Sex-Specific Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blocker Therapy on Arterial Function in Hypertension: CALIBREX Trial. Hypertension. 2022;79:2316-2327. https://doi.org/10.1161/HYPERTENSIONAHA. 122.19105.
Hajjar I, Okafor M, McDaniel D, et al. Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial. JAMA Network Open. 2020;3(8):e2012252. https://doi.org/10.1001/jamanetworkopen.2020.12252.
Zhou Z, Orchard SG, Nelson MR, Fravel MA, Ernst ME. Angiotensin Receptor Blockers and Cognition: a Scoping Review. Current Hypertension Reports. 2024;26:1-19. https://doi.org/10.1007/s11906-023-0 1266-0.
The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med. 2008;358(15):1547-1559. https://doi.org/10.1056/NEJMoa0801317.
Escobar C, Mazón P, Rivadulla C, Chandrappa S. The role of eprosartan in the management of essential hypertension: literature review and expert opinion. Expert Review of Cardiovascular Therapy. 2024;22:10, 575-587. https://doi.org/10.1080/14779072.2024.2418298.
Kehoe PG, Turner N, Howden B, va boshqalar. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer’s disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021;20(11):895-906. https://doi.org/10.1016/S1474-44 22(21)00263-0.
Yoo S, Stremlau M, Pinto A, Woo H, Curtis O, van Praag H. Effects of Combined Anti-Hypertensive and Statin Treatment on Memory, Fear Extinction, Adult Neurogenesis, and Angiogenesis in Adult and Middle-Aged Mice. Cells. 2021;10(7):1778. https://doi.org/10.3390/cells10071778.
Dewan P, Shen L, Ferreira JP, Jhund PS, Anand IS, Chandra A, Chiang LM, Claggett B, Desai AS, Gong J, et al. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF. Circulation. 2024;150:272-282. https://doi.org/10.1161/CIRCULATIONAHA.124.068774.
Carcel C, Clancy L, Harris K, et al. Randomised controlled decentralised feasibility trial of a fixed low-dose combination antihypertensive drug strategy to attenuate cognitive decline in high-risk adults. BMJ Open 2024;14:e080862. https://doi.org/10.1136/bmjopen-2023-080862.
H.F.Yusupova, G.Zh. Abdullaeva*, G.A. Khamidullaeva, F.A.Alikhodzhaeva.Effect of Nitrendipine and Amlodipine on Cognitive Functions of Patients with Arterial Hypertension. International Journal of Biomedicine, 2023; 13(2): 217–223. https://doi.org/10.21103/Article13(2)_OA2.
Copyright (c) 2025 М.И. Атоева, Г.Ж. Абдуллаева, Х.Ф. Юсупова, И.В. Ибрагимова (Автор)
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution» (««Atribut») 4.0 Butun dunyo bo'ylab.